News
PYXS
2.900
0.00%
0.000
Pyxis Oncology launches offering for phase 3 cancer trial; stock tumbles
Seeking Alpha · 10h ago
Pyxis Oncology announces common stock offering, no amount given
TipRanks · 10h ago
Pyxis Oncology Launches Public Offering Of Common Stock/Pre-Funded Warrants And Warrants To Fund MICVO Phase 3 Development; No Terms Disclosed
Benzinga · 10h ago
Pyxis Oncology Terminates $150M ATM Offering, Says As Of The Date Of This Supplement, We Have Not Sold Any Shares Of Our Common Stock Pursuant To The Sales Agreement
Benzinga · 10h ago
Weekly Report: what happened at PYXS last week (0921-0925)?
Weekly Report · 1d ago
LifeSci Capital Remains a Buy on Pyxis Oncology (PYXS)
TipRanks · 3d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (PYXS), Moderna (MRNA) and Eli Lilly & Co (LLY)
TipRanks · 09/22 13:30
Weekly Report: what happened at PYXS last week (0914-0918)?
Weekly Report · 09/21 09:21
Pyxis Oncology: MICVO’s Emerging Clinical Profile and Strong Physician Receptivity Support Buy Rating and Unchanged $6 Price Target
TipRanks · 09/16 21:57
Pyxis Oncology Consensus Price Target Increased by 16.92% to $8.61
NASDAQ · 09/15 02:18
Weekly Report: what happened at PYXS last week (0907-0911)?
Weekly Report · 09/14 09:22
Pyxis Oncology: Setbacks Costing Nearly 2 Years Of Recovery
Seeking Alpha · 09/11 17:43
Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials
NASDAQ · 09/11 16:06
Analysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Pyxis Oncology (PYXS)
TipRanks · 09/11 01:50
Pyxis Oncology Is Maintained at Outperform by Wedbush
Dow Jones · 09/10 13:09
Pyxis Oncology Price Target Raised to $8.00/Share From $6.00 by Wedbush
Dow Jones · 09/10 13:09
Wedbush Maintains Outperform on Pyxis Oncology, Raises Price Target to $8
Benzinga · 09/10 12:59
Pyxis Oncology Price Target Raised to $8.00/Share From $7.00 by HC Wainwright & Co.
Dow Jones · 09/10 10:40
Pyxis Oncology Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 09/10 10:40
HC Wainwright & Co. Maintains Buy on Pyxis Oncology, Raises Price Target to $8
Benzinga · 09/10 10:32
More
Webull provides a variety of real-time PYXS stock news. You can receive the latest news about Pyxis Oncology, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PYXS
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.